Geron Corporation (GERN)

NMS – Real Time Price. Currency in USD

1.32

-0.05 (-3.65%)

At close: Jun 26, 2026, 4:00 PM EDT

1.32

-0.00 (-0.10%)

After-hours: Jun 26, 2026, 7:57 PM EDT

08.06.2026

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

01.06.2026

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m.

01.06.2026

Geron: Time To Reconsider This Oversold Biotech

Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.

19.05.2026

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

18.05.2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

13.05.2026

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

There is no data to display

Press releases

18.05.2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12.05.2026

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population

06.05.2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m.

20.04.2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation (GERN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Geron Corporation (GERN)

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Geron: Time To Reconsider This Oversold Biotech

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Geron: Time To Reconsider This Oversold Biotech

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Geron Corporation (GERN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Geron Corporation (GERN)

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Geron: Time To Reconsider This Oversold Biotech

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Geron: Time To Reconsider This Oversold Biotech

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)